|
|
| (5 intermediate revisions by 2 users not shown) |
| Line 4: |
Line 4: |
| '''For patient information, click [[Amyloidosis (patient information)|here]]''' | | '''For patient information, click [[Amyloidosis (patient information)|here]]''' |
|
| |
|
| {{CMG}}; {{AE}} {{SHH}} | | {{CMG}}; {{AE}}{{Sab}}, {{HK}}, {{SHH}} |
| | | |
| ==Overview==
| | {{SK}} |
| In 1639, Nicolaus Fontanus [[Autopsy|autopsied]] a young man who had [[ascites|ascitis]], [[jaundice]], [[liver abscess]] and [[splenomegaly]] and his report has been the first description of amyloidosis. and in 1959, Cohen and Calkins assessed an ultra-thin sections of amyloidotic tissues by [[Electron microscope|electron microscopic]] examination. Amyloidosis may be classified based on [[precursor]] of amyloidogenic [[protein]] into different subtypes, include AL amyloidosis ([[Light chain|Light chains]] of [[Immunoglobulin|immunoglobulines]]), AA amyloidosis ([[Serum amyloid A|Serum amyloid A protein]]), AF amyloidosis (Mutant [[transthyretin]], [[Apolipoprotein A1|A1-apolipoprotein,]] [[gelsolin]], [[fibrinogen]], etc.), ATTRwt amyloidosis (Wild-type [[transthyretin]]), and AH amyloidosis (ß2-microglobulin). Amyloidosis also may classified by their extension of organ involvement as systemic amyloidosis ([[AL amyloidosis|primary amyloidosis]], [[AA amyloidosis|secondary amyloidosis]], hereditary amyloidosis) and Organ-specific amyloidosis ([[cardiac amyloidosis]], [[Hepatic amyloidosis with intrahepatic cholestasis|hepatic amyloidosis]], [[renal amyloidosis]], etc.). [[Amyloid]] is an abnormal insoluble [[extracellular]] [[protein]] that deposits in the different tissues and causes organic dysfunction. These abnormal [[Amyloid|amyloids]] derived from misfolding and aggregation of normally soluble [[Protein|proteins]]. In systemic amyloidosis, [[amyloid]] gradually accumulate and [[amyloid]] deposition is widespread in the viscera, [[blood vessel]] walls, and in the different [[Connective tissue|connective tissues]]. In organ-specific amyloidoses, [[amyloid]] deposition occurs only in the origin organ or tissue of [[precursor]] [[protein]]. In microscopy pathology of amyloidosis, [[amyloid]] is detectable as typical green [[birefringence]] under [[Polarization|polarized]] light after [[Congo red]] staining, linear non-branching [[Fibril|fibrils]], distinct [[X-rays|X-ray]] diffraction pattern consistent with Pauling's model of a cross-beta fibril.
| |
|
| |
|
| == Historical Perspective == | | ==[[Amyloidosis overview|Overview]]== |
| *In 1639, Nicolaus Fontanus [[Autopsy|autopsied]] a young man who had [[ascites|ascitis]], [[jaundice]], [[liver abscess]] and [[splenomegaly]] and his report has been the first description of amyloidosis.
| |
| *In 1854, Rudolph Virchow introduced the term of [[amyloid]] as an macroscopic abnormality in some tissues.
| |
| *In 1867, Weber reported the first case of amyloidosis associated with [[multiple myeloma]].<ref name="pmid218384133">{{cite journal |vauthors=Kyle RA |title=Amyloidosis: a brief history |journal=Amyloid |volume=18 Suppl 1 |issue= |pages=6–7 |date=June 2011 |pmid=21838413 |doi=10.3109/13506129.2011.574354001 |url=}}</ref>
| |
| *In 1922, Bennhold introduced [[Congo red|Congo red staining]] of [[amyloid]] that remains the [[Gold standard (test)|gold standard]] for [[diagnosis]].
| |
| *In 1959, Cohen and Calkins used ultra-thin sections of amyloidotic tissues and assessed by [[Electron microscope|electron microscopic]] examination, explained the presence of non-branching [[Fibril|fibrils]] with indeterminate length and variable width.<ref name="pmid10940217">{{cite journal |vauthors=Sipe JD, Cohen AS |title=Review: history of the amyloid fibril |journal=J. Struct. Biol. |volume=130 |issue=2-3 |pages=88–98 |date=June 2000 |pmid=10940217 |doi=10.1006/jsbi.2000.4221 |url=}}</ref><ref name="pmid218384133">{{cite journal |vauthors=Kyle RA |title=Amyloidosis: a brief history |journal=Amyloid |volume=18 Suppl 1 |issue= |pages=6–7 |date=June 2011 |pmid=21838413 |doi=10.3109/13506129.2011.574354001 |url=}}</ref>
| |
|
| |
|
| == Classification == | | ==[[Amyloidosis historical perspective|Historical Perspective]]== |
|
| |
|
| === Amyloidosis may be classified based on [[precursor]] of amyloidogenic [[protein]] into different subtypes, include: === | | ==[[Amyloidosis classification|Classification]]== |
| {| class="wikitable"
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Type
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Amyloidogenic protein/ fibril
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical syndrome
| |
| |-
| |
| | style="background:#DCDCDC;" |[[Primary amyloidosis|'''AL (primary amyloidosis)''']]
| |
| |[[Light chain|Light chains]] of [[Immunoglobulin|immunoglobulines]] (most common type)
| |
| |[[Monoclonal gammopathy]]
| |
| |-
| |
| | style="background:#DCDCDC;" |[[AA amyloidosis|'''AA (secondary amyloidosis)''']]
| |
| |[[Serum amyloid A|Serum amyloid A protein]]
| |
| |[[Chronic inflammation|Chronic inflammatory diseases]]
| |
| |-
| |
| | style="background:#DCDCDC;" |'''AF'''
| |
| |Mutant [[transthyretin]], [[Apolipoprotein A1|A1-apolipoprotein,]] [[gelsolin]], [[fibrinogen]], etc.
| |
| |Familial [[polyneuropathy]]/[[cardiomyopathy]]/[[nephropathy]]
| |
| |-
| |
| | style="background:#DCDCDC;" |'''ATTRwt'''
| |
| |Wild-type [[transthyretin]]
| |
| |[[Senile]] [[restrictive cardiomyopathy]] _ [[Transthyretin]]-related amyloidosis wild-type
| |
| |-
| |
| | style="background:#DCDCDC;" |'''AH'''
| |
| |ß2-microglobulin
| |
| |Long-term [[hemodialysis]]
| |
| |}
| |
|
| |
|
| === Amyloidosis also may classified by their extension of organ involvement as below: === | | ==[[Amyloidosis pathophysiology|Pathophysiology]]== |
| {| class="wikitable"
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Classification
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |subtypes
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes
| |
| ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
| |
| |-
| |
| ! rowspan="3" style="background:#DCDCDC;" |Systemic amyloidosis
| |
| ! style="background:#DCDCDC;" |[[AL amyloidosis|Primary amyloidosis (AL)]]
| |
| |
| |
| * Aggregation and deposition of [[immunoglobulin]] [[Light chain|light chains]] that usually produced by [[plasma cell]] clones
| |
| |
| |
| * [[Nephrotic syndrome]]
| |
| * [[Restrictive cardiomyopathy]]
| |
| * [[Peripheral neuropathy]]
| |
| * [[Hepatomegaly]] with elevated [[liver enzymes]]
| |
| * [[Macroglossia]]
| |
| * [[Purpura]] and an unexplained [[Hemorrhagic diathesis|bleeding diathesis]]
| |
| |-
| |
| ! style="background:#DCDCDC;" |[[AA amyloidosis|Secondary amyloidosis (AA)]]
| |
| |
| |
| * Chronic [[inflammation]] ([[Tuberculosis|TB]], [[familial mediterranean fever]], [[rheumatoid arthritis]] and [[multiple myeloma]])
| |
| |
| |
| * [[Nephrotic syndrome]]
| |
| * [[Congestive heart failure|Heart failure]]
| |
| |-
| |
| ! style="background:#DCDCDC;" |[[Heredity|Hereditary]] amyloidosis
| |
| |
| |
| * Amyloidogenic [[Mutation|mutations]] and subsequently deposition of [[Amyloid|amyloids]]
| |
| |
| |
| * [[Congestive heart failure|Heart failure]]
| |
| * [[Cardiac arrhythmia|Arrhythmia]]
| |
| |-
| |
| ! rowspan="5" style="background:#DCDCDC;" |Organ-specific amyloidosis
| |
| ! style="background:#DCDCDC;" |[[Renal amyloidosis]]
| |
| | rowspan="5" |
| |
| * [[AL amyloidosis|Immunoglobulin light-chain amyloidosis (AL amyloidosis)]]
| |
| * [[Transthyretin-related hereditary amyloidosis|Transthyretin-related amyloidosis]] (associated with familial/mutant or senile/wild-type [[Transthyretin|TTR]])
| |
| |
| |
| * [[Proteinuria]]
| |
| * [[Nephrotic syndrome]]
| |
|
| |
|
| * [[Chronic renal failure]]
| | ==[[Amyloidosis causes|Causes]]== |
| |-
| |
| ! style="background:#DCDCDC;" |[[Cardiac amyloidosis]]
| |
| | | |
| * [[Systolic dysfunction]]
| |
|
| |
|
| * [[Diastolic dysfunction]]
| | ==[[Amyloidosis differential diagnosis|Differentiating Amyloidosis from other Diseases]]== |
| * [[Cardiac arrhythmia|Arrhythmia]]
| |
| |-
| |
| ! style="background:#DCDCDC;" |[[Hepatic amyloidosis with intrahepatic cholestasis|Hepatic amyloidosis]]
| |
| |
| |
| * [[Hepatomegaly]]
| |
| * Elevated [[liver enzymes]]
| |
| |-
| |
| ! style="background:#DCDCDC;" |Amyloid neuropathy
| |
| |
| |
| * [[Peripheral neuropathy]] and [[autonomic neuropathy]]
| |
| * [[Neurodegenerative disease|Neurodegenerative disorders]]
| |
| ** [[Parkinson's disease|Parkinson]], [[Alzheimer's disease|Alzheimer]], and [[Huntington's disease]]
| |
| |-
| |
| ! style="background:#DCDCDC;" |Gastrointestinal amyloidosis
| |
| |
| |
| * Nonspecific findings
| |
| ** [[Dyspepsia]], [[abdominal pain]], [[diarrhea]], [[malabsorption]]
| |
| |}
| |
|
| |
|
| == Pathophysiology == | | ==[[Amyloidosis epidemiology and demographics|Epidemiology and Demographics]]== |
| *[[Amyloid]] is an abnormal insoluble [[extracellular]] [[protein]] that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes.
| |
| *These abnormal [[Amyloid|amyloids]] derived from misfolding and aggregation of normally soluble [[Protein|proteins]].
| |
| *[[Amyloid]] deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.
| |
| ===Systemic Amyloidosis===
| |
| *In systemic amyloidosis, [[amyloid]] gradually accumulate and [[amyloid]] deposition is widespread in the viscera, [[blood vessel]] walls, and in the different [[Connective tissue|connective tissues]].<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref><ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref>
| |
| ====Primary Amyloidosis (AL)====
| |
| *[[AL amyloidosis|Primary (AL) amyloidosis)]] is the most common type of amyloidosis. It results from aggregation and deposition of monoclonal [[Immunoglobulin|immunoglobulin (Ig)]] [[Light chain|light chains]] that usually produced by [[plasma cell]] clones.
| |
| *Change in the [[secondary structure]] or [[tertiary structure]] of a monoclonal [[light chain]] results in abnormal folding of the [[light chain]] that abnormally form [[amyloid]] [[Fibril|fibrils]].
| |
| *This type of amyloidosis most frequently involve the [[kidney]] (usually [[proteinuria]] with the [[nephrotic syndrome]]) and the [[heart]].
| |
| *In [[AL amyloidosis|primary (AL) amyloidosis]] survival rate depends on:
| |
| **Type of organ involvement ([[amyloid]] heart disease is the main prognostic factor)
| |
| **The severity of different organs involvement
| |
| **[[Hematology|Haematological]] response to treatment
| |
| *The median [[Survival analysis|survival]] of patients with [[AL amyloidosis]] is aproximately 3.8 years.
| |
| For more information about primary amyloidosis click [[AL amyloidosis|'''here''']].
| |
|
| |
|
| ====Secondary Amyloidosis (AA)==== | | ==[[Amyloidosis risk factors|Risk Factors]]== |
| *[[AA amyloidosis|Secondary amyloidosis]] is associated with chronic [[inflammation]] (such as [[tuberculosis]] or [[rheumatoid arthritis]]).<ref name="pmid116772762">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref>
| |
| *[[AA amyloidosis|Secondary or reactive amyloidosis (AA)]] is approximately 45% of all systemic amyloidosis.
| |
| *[[Pathogenesis]] of [[AA amyloidosis|secondary amyloidosis]] is multifactorial that include:
| |
| **[[Primary structure]] of the [[precursor]] protein
| |
| **Acute phase response
| |
| **Nonfibril [[Protein|proteins]] ([[amyloid]] P component, [[Apolipoprotein E|apo E]], [[Glycosaminoglycan|GAGs]], [[Proteoglycan|proteoglycans]] and [[basement membrane]] [[Protein|proteins]])
| |
| **[[Receptor (biochemistry)|Receptors]]
| |
| **[[Lipid metabolism]]
| |
| **[[Protease|Proteases]]
| |
| For more information about secondary amyloidosis click '''[[AA amyloidosis|here]]'''.
| |
|
| |
|
| ====Hereditary Amyloidosis==== | | ==[[Amyloidosis screening|Screening]]== |
| *Hereditary (or familial) amyloidosis are [[Autosome|autosomal]] [[Dominance relationship|dominant]] diseases that [[inherited]] variant [[Protein|proteins]] cause the production and deposition of [[amyloid]] fibrils.<ref name="pmid116772762">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref>
| |
| *Hereditary amyloidosis are due to amyloidogenic [[Mutation|mutations]] and subsequently deposition of [[Amyloid|amyloids]], include:
| |
| **[[Transthyretin|Transthyretin (TTR)]] (most common [[inherited]] [[mutation]])
| |
| **[[Fibrinogen]]
| |
| **[[Apolipoprotein A1]]
| |
| **[[Apolipoprotein A2]]
| |
| **[[Lysozyme]]
| |
| **[[Gelsolin]] [[Gene|genes]]
| |
| ===Organ-specific Amyloidosis===
| |
| *In this type of amyloidoses, [[amyloid]] deposition occurs only in the origin organ or tissue of [[precursor]] [[protein]].
| |
| *Some [[Neurodegenerative disease|neurodegenerative disorders]] such as [[Parkinson's disease]], [[Alzheimer's disease|Alzheimer]], and [[Huntington's disease]] may occur in localised amyloidosis.
| |
|
| |
|
| *Localised amyloidoses can accure due to deposition of [[intracellular]] and/or [[extracellular]] [[amyloid]].
| | ==[[Amyloidosis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
| **[[Huntington's disease]]: [[intracellular]] [[protein]] deposition
| |
| **[[Parkinson's disease]]: [[intracellular]] [[protein]] deposition
| |
| **[[Alzheimer's disease]]: [[intracellular]] ([[Tau protein]] [[Fibril|fibrils]]) and [[extracellular]] ([[amyloid]] β fibrils) deposition
| |
| ===Microscopic Pathology===
| |
| In microscopy pathology of amyloidosis, [[amyloid]] is detectable as:<ref name="pmid119640392">{{cite journal |vauthors=Röcken C, Shakespeare A |title=Pathology, diagnosis and pathogenesis of AA amyloidosis |journal=Virchows Arch. |volume=440 |issue=2 |pages=111–122 |date=February 2002 |pmid=11964039 |doi=10.1007/s00428-001-0582-9 |url=}}</ref><ref name="pmid116772762">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref>
| |
| *Typical green [[birefringence]] under [[Polarization|polarized]] light after [[Congo red]] staining (appears in red under normal light)
| |
| *Linear non-branching [[Fibril|fibrils]] (indefinite length with an approximately same diameter)
| |
| *Distinct [[X-rays|X-ray]] diffraction pattern consistent with Pauling's model of a cross-beta fibril
| |
| *
| |
|
| |
|
| ==Epidemiology and Demographics== | | ==Diagnosis== |
| ===Incidence===
| | [[Amyloidosis diagnostic study of choice|Diagnostic study of choice]] | [[Amyloidosis history and symptoms|History and Symptoms]] | [[Amyloidosis physical examination|Physical Examination]] | [[Amyloidosis laboratory findings|Laboratory Findings]] | [[Amyloidosis electrocardiogram|Electrocardiogram]] | [[Amyloidosis x ray|X-ray]] | [[Amyloidosis echocardiography and ultrasound|Echocardiography and Ultrasound]] | [[Amyloidosis CT scan|CT scan]] | [[Amyloidosis MRI|MRI]] | [[Amyloidosis other imaging findings|Other Imaging Findings]] | [[Amyloidosis other diagnostic studies|Other Diagnostic Studies]] |
|
| |
|
| *The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.<ref name="pmid1167727622">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref>
| | ==Treatment== |
| | | [[Amyloidosis medical therapy|Medical Therapy]] | [[Amyloidosis surgery|Surgery]] | [[Amyloidosis primary prevention|Primary Prevention]] | [[Amyloidosis secondary prevention|Secondary Prevention]] | [[Amyloidosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Amyloidosis future or investigational therapies|Future or Investigational Therapies]] |
| ===Prevalence===
| |
| | |
| *The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
| |
| *In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
| |
| *The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
| |
| | |
| ===Mortality rate===
| |
| | |
| *The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.<ref name="pmid164091472">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref>
| |
| | |
| === Age===
| |
| | |
| *In amyloidosis, the mean age of presentation is 55-60 years.<ref name="pmid214940832">{{cite journal |vauthors=Shin YM |title=Hepatic amyloidosis |journal=Korean J Hepatol |volume=17 |issue=1 |pages=80–3 |date=March 2011 |pmid=21494083 |pmc=3304630 |doi=10.3350/kjhep.2011.17.1.80 |url=}}</ref>
| |
| | |
| ===Race===
| |
| | |
| *Hereditary amyloidosis subtypes include a substitution of an amino acid that is detected in approximately 4% of the black population.<ref name="pmid116772763">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref>
| |
| *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
| |
| | |
| ===Gender ===
| |
| | |
| *Men are more commonly affected by amyloidosis than women.<ref name="pmid21494083">{{cite journal |vauthors=Shin YM |title=Hepatic amyloidosis |journal=Korean J Hepatol |volume=17 |issue=1 |pages=80–3 |date=March 2011 |pmid=21494083 |pmc=3304630 |doi=10.3350/kjhep.2011.17.1.80 |url=}}</ref>
| |
|
| |
|
| ==Case Studies== | | ==Case Studies== |
| [[Amyloidosis case study one|Case #1]] | | [[Amyloidosis case study one|Case #1]] |
|
| |
|
| [[Category:Medicine]] | | [[Category:Disease]] |
| [[Category:Up-To-Date]] | | [[Category:Cardiology]] |
| <references />
| | [[Category:Pulmonology]] |
| | [[Category:Immunology]] |